Zequn Sun

Dr. Zequn Sun


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in JCO Oncology Practice
Verified
Journal Article
Closed access
LGLaila A. Gharzai
Laila A. Gharzai
YLYingzhe (Alex) Liu
Yingzhe (Alex) Liu
ZSZequn Sun
Zequn Sun
LMLeila Mady
Leila Mady
MMMichelle Mohn
Michelle Mohn
GSGelareh Sadigh
Gelareh Sadigh
PURPOSE: Financial toxicity is an important issue in cancer that affects quality of life and treatment adherence. Screening can identify patients at risk but consensus on appropriate timing or methods is lacking. METHODS: We sent an anonymous survey to e-mail subscribers of a nationwide breast cancer–specific philanthropic organization in July 2023 asking about financial toxicity screening preferences. Frequencies, percentages, and medians were calculated for categorical and continuous variables. RESULTS: Of 5,774 potential participants, 738 respondents with a confirmed cancer diagnosis participated (12.7% response rate). Participants were 93% female (n = 690), had a median age of 50 years (IQR, 44-57), were 57% non-Hispanic White (n = 418), 20% Black/African-American (n = 149), 9.2% Hispanic (n = 68). 93% confirmed a breast cancer diagnosis (n = 689), and 54% were currently undergoing treatment (n = 400). Most indicated not being asked about financial stressors by (58%, n = 425) and not receiving assistance from their care team (68%, n = 498). Most preferred for providers to reach out regarding financial needs (83%, n = 615). Most wished for these discussions to take place early (when first diagnosed [45%, n = 334] or when treatment selected [37%, n = 275]) and to be asked frequently (each appointment [42%, n = 312] or once per month [36%, n = 268]). Participants felt most comfortable discussing financial needs with a social worker or patient/financial navigator (92%, n = 679), in person (75%, n = 553), or via telephone (65%, n = 479). CONCLUSION: Patients in this sample primarily consisting of women with breast cancer desired financial screening to occur early, often, and to be initiated by their providers. Patient preferences can inform optimal implementation of financial toxicity screening practices. Continued work refining best practices for financial toxicity screening should incorporate these patient preferences.

24 January 2025 in JCO Oncology Practice
Verified
Journal Article
Closed access
LGLaila A. Gharzai
Laila A. Gharzai
LMLeila Mady
Leila Mady
MAMaria Armache
Maria Armache
ZSZequn Sun
Zequn Sun
RJReshma Jagsi
Reshma Jagsi
RHRichard W Hass
Richard W Hass
PURPOSE: Financial toxicity (FT) has been linked to higher symptom burden and poorer clinical outcomes for patients with cancer. Despite the availability of validated tools to measure FT, a simple screen remains an unmet need. We evaluated item 12 (“My illness has been a financial hardship to my family and me”) of the COmprehensive Score for Financial Toxicity (COST) measure as a single-item FT screening measure. METHODS: In this secondary analysis, 711 patients with cancer (690 with breast cancer) were recruited via a web-based survey from a philanthropic organization. COST items 1-11 were scored according to Functional Assessment of Chronic Illness Therapy scoring guidelines, with lower scores indicating worse FT. Analyses focused on establishing a correlation, examining item properties, and sensitivity/specificity of item 12 relative to the total COST score. RESULTS: Item 12 had a correlation of r = 0.53 with the COST-11 score, and an increase of one point on item 12 is associated with a decrease of approximately three total points on the full scale ( b , 3.35; P < .001; adjusted R 2 , 0.28). Item analysis with the graded-response item in response theory modeling showed very good discrimination ( a , 2.096) for item 12, indicating that it can reliably distinguish between low and high FT in patients. Sensitivity ranged between 75.6% and 95.7% on all item 12 thresholds to screen positive for FT using two COST cutoffs as criteria. Maximizing both sensitivity and specificity was to be found for higher item 12 scores. CONCLUSION: To our knowledge, this is the first validation of a single-item screening measure for FT. Overall, these results illustrate that item 12 from the COST measure is a good candidate for a single-item screener. Clinicians can choose among item 12 screening thresholds depending on their tolerance for low specificity.

1 June 2025 in Journal of Urology
Verified
Journal Article
Open access
SSSarah Sandlow
Sarah Sandlow
SCSamuel Carbunaru
Samuel Carbunaru
ZSZequn Sun
Zequn Sun
BOBernice Ofori
Bernice Ofori
YLYingzhe Liu
Yingzhe Liu
AMAdam B. Murphy
Adam B. Murphy
Prostate Imaging Reporting and Data System (PIRADS) v2.1 scoring with multiparametric MRI (mpMRI) has a pooled 90% negative predictive value (NPV). PSA density (PSAD) ≤0.15ng/ml/cm3 has been shown to enhance mpMRI's NPV in non-Black men. Populations with higher disease prevalence are known to have lower NPVs. Given that Black men have higher PCa prevalence, we evaluate sensitivity and NPV of mpMRI in Black vs. non-Black men to assess possible mpMRI performance differences. As an exploratory objective, we investigate PSAD thresholds providing ≥90% sensitivity in Black men. We prospectively recruited Black and non-Black men referred to outpatient urology clinics for abnormal PSA or prostate exam in three similar biomarker validation studies from 2017-23 before MRI-informed diagnostic prostate biopsy. We combined the research cohorts with a retrospective clinical cohort of clinically similar Black and non-Black men from one academic institution who also underwent mpMRIs and MRI-informed biopsies. MRIs were scored using PIRADS version 2.0 or 2.1. Our analysis included 286 Black men and 965 non-Black men with PSA ≤15.0ng/ml. PIRADS <3 had an NPV of 77.1% versus 87.6% and a sensitivity of 90.7% vs. 96.3% for GG2-5 PCa in Black versus non-Black men, respectively (both p <0.05). Using PSAD ≥0.09 for Black men with PIRADS 1-2 lesions increased sensitivity to 92.9%. PIRADS <3 has a lower NPV and sensitivity in Black men. For negative prostate MRIs, PSAD ≥0.09 may be a better threshold for safe biopsy deferral in Black men to maintain a ≥90% sensitivity.

30 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CVChetan Vakkalagadda
Chetan Vakkalagadda
DDDanielle Dressler
Danielle Dressler
ZSZequn Sun
Zequn Sun
JFJoseph Fuchs
Joseph Fuchs
YLYingzhe Liu
Yingzhe Liu
NMNisha A. Mohindra
Nisha A. Mohindra
Purpose: Broad-based molecular testing with next-generation sequencing (NGS) is now the standard of care in advanced non-small cell lung cancer (NSCLC). Two approaches to molecular testing are (1) reflexive testing at pathologic NSCLC confirmation, often using an in-house molecular panel, and (2) send-out testing to private vendors, ordered by a clinician. This study explored the outcomes with reflex versus send-out testing. Methods: A retrospective chart review was conducted of patients diagnosed with de novo stage IV NSCLC in 2019 and 2020 at three hospitals in the same system, one academic hospital (Northwestern Memorial Hospital, or NMH) utilizing reflex, in-house NGS, and two community-based hospitals (Central DuPage Hospital, or CDH, and Delnor, or D) sending out tissue samples for testing. The outcomes assessed were the time from biopsy to results, biopsy to treatment, the incidence of first-line targetable mutations and the use of first-line targeted therapies, and overall survival. Results: In total, 191 patients met the inclusion criteria, 85 at NMH, 106 at CDH + D, and in total, 131 in 2019 and 60 in 2020. The time to results was significantly shorter with reflexive NGS when compared with send-out testing; the time to treatment was also shorter but not statistically significant. At CDH + D, the time to results was significantly shorter with a limited panel than with comprehensive testing, but the time to treatment was similar. NGS testing rates were 95% at NMH and 84.5% at CDH + D (p = 0.009), with 31.0% at NMH receiving 1L targeted therapies versus 20.8% at CDH + D (p = 0.08). In 2019, the median time from biopsy to treatment was 35 days at NMH and 38 days at CDH and Delnor; in 2020, time to treatment was 26 days and 37 days, respectively. Overall survival trended longer in 2020 relative to 2019 independent of site. Conclusion: Reflexive NGS testing is associated with a shorter time to actionable results and higher rates of first-line targetable mutations than send-out testing. In practices with send-out testing, limited panels had slightly faster turnaround times but no difference in time to treatment. If resources allow, reflexive NGS should be considered in healthcare systems for patients with NSCLC.

15 September 2023 in Statistics in Medicine
Verified
Journal Article
Open access
ZSZequn Sun
Zequn Sun
DCDongjun Chung
Dongjun Chung
BNBrian Neelon
Brian Neelon
AMAndrew Millar‐Wilson
Andrew Millar‐Wilson
SEStephen P. Ethier
Stephen P. Ethier
Gary HardimanGary Hardiman
Gary Hardiman
In recent years, comprehensive cancer genomics platforms, such as The Cancer Genome Atlas (TCGA), provide access to an enormous amount of high throughput genomic datasets for each patient, including gene expression, DNA copy number alterations, DNA methylation, and somatic mutation. While the integration of these multi‐omics datasets has the potential to provide novel insights that can lead to personalized medicine, most existing approaches only focus on gene‐level analysis and lack the ability to facilitate biological findings at the pathway‐level. In this article, we propose Bayes‐InGRiD (Bayesian Integrative Genomics Robust iDentification of cancer subgroups), a novel pathway‐guided Bayesian sparse latent factor model for the simultaneous identification of cancer patient subgroups (clustering) and key molecular features (variable selection) within a unified framework, based on the joint analysis of continuous, binary, and count data. By utilizing pathway (gene set) information, Bayes‐InGRiD does not only enhance the accuracy and robustness of cancer patient subgroup and key molecular feature identification, but also promotes biological understanding and interpretation. Finally, to facilitate an efficient posterior sampling, an alternative Gibbs sampler for logistic and negative binomial models is proposed using Pólya‐Gamma mixtures of normal to represent latent variables for binary and count data, which yields a conditionally Gaussian representation of the posterior. The R package “INGRID” implementing the proposed approach is currently available in our research group GitHub webpage (https://dongjunchung.github.io/INGRID/).

Verified
Journal Article
Open access
PDF file
ASAnthony Smith
Anthony Smith
KDKatrina Dobinda
Katrina Dobinda
SCSi Chen
Si Chen
PZPeter Zieba
Peter Zieba
Tatjana PauneskuTatjana Paunesku
Tatjana Paunesku
GWGayle E Woloschak
Gayle E Woloschak
Iron redistribution in the intestine after total body irradiation is an established phenomenon. However, in the literature, there are no reports about the use of X-ray fluorescence microscopy or equivalent techniques to generate semi-quantitative 2D maps of iron in sectioned intestine samples from irradiated mice. In this work, we used X-ray fluorescence microscopy (XFM) to map the elemental content of iron as well as phosphorus, sulfur, calcium, copper and zinc in tissue sections of the small intestine from eight-week-old BALB/c male mice that developed gastrointestinal acute radiation syndrome (GI-ARS) in response to exposure to 8 Gray of gamma rays. Seven days after irradiation, we found that the majority of the iron is localized as hot spots in the intercellular regions of the area surrounding crypts and stretching between the outer perimeter of the intestine and the surface cell layer of villi. In addition, this study represents our current efforts to develop elemental cell classifiers that could be used for the automated generation of regions of interest for analyses of X-ray fluorescence maps. Once developed, such a tool will be instrumental for studies of effects of radiation and other toxicants on the elemental content in cells and tissues. While XFM studies cannot be conducted on living organisms, it is possible to envision future scenarios where XFM imaging of single cells sloughed from the human (or rodent) intestine could be used to follow up on the progression of GI-ARS.